Pharmaceutical effect of manganese porphyrins on manganese superoxide dismutase deficient mice.
Mice lacking manganese-superoxide dismutase (Mn-SOD) activity exhibit typical pathology of dilated cardiomyopathy (DCM). In the present study, the structure-activity relationship between the water-soluble manganese (Mn) porphyrin with SOD activity and the in vivo pharmaceutical effect on DCM is reported. The Mn-SOD-deficient mice were treated with Mn-porphyrins for 3 weeks. The treatment of a Mn-porphyrin, MnM2Py(2)P, suppressed the progression of cardiac dilation. These results suggest that the Mn-porphyrin MnM2Py(2)P treatment is proposed as a potential therapy for DCM.
Department of Applied Chemistry, Tokyo Metropolitan University, Minami-Osawa, Hachioji, Tokyo, Japan.
Natsumi
N
Hayakawa
Shoichiro
S
Asayama
Yoshihiro
Y
Noda
Takahiko
T
Shimizu
Hiroyoshi
H
Kawakami
D000818:Animals; D002311:Cardiomyopathy, Dilated / Q000188:drug therapy / Q000378:metabolism; D008345:Manganese / Q000494:pharmacology*; D008665:Metalloporphyrins / Q000494:pharmacology*; D051379:Mice; D018384:Oxidative Stress / Q000187:drug effects; D013329:Structure-Activity Relationship; D013482:Superoxide Dismutase / Q000172:deficiency* / Q000378:metabolism*; D014867:Water / Q000737:chemistry
D008665:Metalloporphyrins; D014867:Water; D008345:Manganese; D013482:Superoxide Dismutase